ClinConnect ClinConnect Logo
Search / Trial NCT06373913

The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom

Launched by KOLDING SYGEHUS · Apr 15, 2024

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the role of a protein called PCSK9 in patients with nephrotic syndrome (NS), a condition that causes high levels of protein in the urine and can lead to high cholesterol levels (hyperlipidemia). Researchers want to find out if patients with NS have higher levels of PCSK9 compared to healthy individuals and whether the amount of PCSK9 relates to how much protein is found in their urine. They will also look at kidney tissue samples to see if PCSK9 levels are increased in those with nephrotic syndrome.

To participate in this study, you need to be at least 18 years old and admitted to the Kolding Sygehus Medical Department or Emergency Department. However, you won't be able to join if you are currently being treated with PCSK9 inhibitors or have any serious health issues that could affect your participation. If you take part, you can expect to provide blood samples to measure PCSK9 levels and possibly undergo a kidney biopsy. This research could help improve our understanding of nephrotic syndrome and its effects on kidney health.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 18 years old
  • Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus.
  • Exclusion Criteria:
  • Refusal to give informed consent
  • Treatment with PCSK9 inhibitors
  • Any acute or chronic condition that would limit the ability of the patient to participate in the study
  • Control group: proteinuria

About Kolding Sygehus

Kolding Sygehus is a leading healthcare institution in Denmark, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong commitment to scientific excellence and ethical standards, Kolding Sygehus collaborates with multidisciplinary teams to conduct rigorous studies across various therapeutic areas. The hospital's state-of-the-art facilities and experienced research staff enable the exploration of new treatments and interventions, contributing to the development of evidence-based practices in healthcare. By fostering partnerships with academic institutions and industry stakeholders, Kolding Sygehus plays a pivotal role in enhancing clinical outcomes and promoting health advancements both locally and globally.

Locations

Kolding, , Denmark

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported